Literature DB >> 28582527

Transcriptional profiles of JIA patient blood with subsequent poor response to methotrexate.

Halima Moncrieffe1,2, Mark F Bennett3, Monica Tsoras1, Lorie K Luyrink1, Anne L Johnson4, Huan Xu3, Jason Dare5, Mara L Becker6, Sampath Prahalad7, Margalit Rosenkranz8, Kathleen M O'Neil9, Peter A Nigrovic10,11, Thomas A Griffin12, Daniel J Lovell4, Alexei A Grom4, Mario Medvedovic3, Susan D Thompson1,2.   

Abstract

Objective: The mechanisms that determine the efficacy or inefficacy of MTX in JIA are ill-defined. The objective of this study was to identify a gene expression transcriptional signature associated with poor response to MTX in patients with JIA.
Methods: RNA sequencing was used to measure gene expression in peripheral blood mononuclear cells collected from 47 patients with JIA prior to MTX treatment and 14 age-matched controls. Differentially expressed baseline genes between responders and non-responders were evaluated. Biological differences between all JIA patients and controls were explored by constructing a signature of differentially expressed genes. Unsupervised clustering and pathway analysis was performed.
Results: A signature of 99 differentially expressed genes (Bonferroni-corrected P < 0.05) capturing the biological differences between all JIA patients and controls was identified. Unsupervised clustering of samples based on this list of 99 genes produced subgroups enriched for MTX response status. Comparing this gene signature with reference signatures from sorted cell populations revealed high concordance between the expression signatures of monocytes and of MTX non-responders. CXCL8 (IL-8) was the most significantly differentially expressed gene transcript comparing all JIA patients with controls (Bonferroni-corrected P = 4.12 × 10-10).
Conclusion: Variability in clinical response to MTX in JIA patients is associated with differences in gene transcripts modulated in monocytes. These gene expression profiles may provide a basis for biomarkers predictive of treatment response.
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com

Entities:  

Keywords:  gene expression; juvenile idiopathic arthritis; methotrexate

Mesh:

Substances:

Year:  2017        PMID: 28582527      PMCID: PMC5850489          DOI: 10.1093/rheumatology/kex206

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  45 in total

1.  Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets.

Authors:  Thomas A Griffin; Michael G Barnes; Norman T Ilowite; Judyann C Olson; David D Sherry; Beth S Gottlieb; Bruce J Aronow; Paul Pavlidis; Claas H Hinze; Sherry Thornton; Susan D Thompson; Alexei A Grom; Robert A Colbert; David N Glass
Journal:  Arthritis Rheum       Date:  2009-07

2.  Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients.

Authors:  Romain Banchereau; Seunghee Hong; Brandi Cantarel; Nicole Baldwin; Jeanine Baisch; Michelle Edens; Alma-Martina Cepika; Peter Acs; Jacob Turner; Esperanza Anguiano; Parvathi Vinod; Shaheen Khan; Gerlinde Obermoser; Derek Blankenship; Edward Wakeland; Lorien Nassi; Alisa Gotte; Marilynn Punaro; Yong-Jun Liu; Jacques Banchereau; Jose Rossello-Urgell; Tracey Wright; Virginia Pascual
Journal:  Cell       Date:  2016-06-02       Impact factor: 41.582

3.  Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis.

Authors:  Sarah Ringold; Pamela F Weiss; Robert A Colbert; Esi Morgan DeWitt; Tzielan Lee; Karen Onel; Sampath Prahalad; Rayfel Schneider; Susan Shenoi; Richard K Vehe; Yukiko Kimura
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-07       Impact factor: 4.794

4.  Preliminary definition of improvement in juvenile arthritis.

Authors:  E H Giannini; N Ruperto; A Ravelli; D J Lovell; D T Felson; A Martini
Journal:  Arthritis Rheum       Date:  1997-07

5.  Safety and efficacy of methotrexate therapy for juvenile rheumatoid arthritis.

Authors:  C D Rose; B H Singsen; A H Eichenfield; D P Goldsmith; B H Athreya
Journal:  J Pediatr       Date:  1990-10       Impact factor: 4.406

Review 6.  Juvenile idiopathic arthritis.

Authors:  Berent Prakken; Salvatore Albani; Alberto Martini
Journal:  Lancet       Date:  2011-06-18       Impact factor: 79.321

7.  SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis.

Authors:  Peter K K Wong; Paul J Egan; Ben A Croker; Kristy O'Donnell; Natalie A Sims; Sarah Drake; Hiu Kiu; Edward J McManus; Warren S Alexander; Andrew W Roberts; Ian P Wicks
Journal:  J Clin Invest       Date:  2006-05-18       Impact factor: 14.808

8.  Sustained stabilization of Interleukin-8 mRNA in human macrophages.

Authors:  Linah Mahmoud; Fatma Al-Enezi; Maher Al-Saif; Arjumand Warsy; Khalid S A Khabar; Edward G Hitti
Journal:  RNA Biol       Date:  2014-02-05       Impact factor: 4.652

9.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.

Authors:  Mark D Robinson; Davis J McCarthy; Gordon K Smyth
Journal:  Bioinformatics       Date:  2009-11-11       Impact factor: 6.937

10.  Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept.

Authors:  Dirk Koczan; Susanne Drynda; Michael Hecker; Andreas Drynda; Reinhard Guthke; Joern Kekow; Hans-Juergen Thiesen
Journal:  Arthritis Res Ther       Date:  2008-05-02       Impact factor: 5.156

View more
  7 in total

Review 1.  Targeting Tregs in Juvenile Idiopathic Arthritis and Juvenile Dermatomyositis-Insights From Other Diseases.

Authors:  Romy E Hoeppli; Anne M Pesenacker
Journal:  Front Immunol       Date:  2019-01-25       Impact factor: 7.561

2.  Association of SLCO1B1 *14 Allele with Poor Response to Methotrexate in Juvenile Idiopathic Arthritis Patients.

Authors:  Laura B Ramsey; Halima Moncrieffe; Chelsey N Smith; Marc Sudman; Miranda C Marion; Carl D Langefeld; Mara L Becker; Susan D Thompson
Journal:  ACR Open Rheumatol       Date:  2019-03-15

Review 3.  The Multi-Omics Architecture of Juvenile Idiopathic Arthritis.

Authors:  Xiaoyuan Hou; Huiqi Qu; Sipeng Zhang; Xiaohui Qi; Hakon Hakonarson; Qianghua Xia; Jin Li
Journal:  Cells       Date:  2020-10-15       Impact factor: 6.600

4.  ZMYND8 mediated liquid condensates spatiotemporally decommission the latent super-enhancers during macrophage polarization.

Authors:  Pan Jia; Xiang Li; Xuelei Wang; Liangjiao Yao; Yingying Xu; Yu Hu; Wenwen Xu; Zhe He; Qifan Zhao; Yicong Deng; Yi Zang; Meiyu Zhang; Yan Zhang; Jun Qin; Wei Lu
Journal:  Nat Commun       Date:  2021-11-11       Impact factor: 14.919

5.  Gene Expression Profiles of Treatment Response and Non-Response in Children With Juvenile Dermatomyositis.

Authors:  Cory Stingl; Jeffrey A Dvergsten; Simon W M Eng; Rae S M Yeung; Marvin J Fritzler; Thomas Mason; Cynthia Crowson; Deepak Voora; Ann M Reed
Journal:  ACR Open Rheumatol       Date:  2022-05-26

6.  Connecting omics signatures and revealing biological mechanisms with iLINCS.

Authors:  Marcin Pilarczyk; Mehdi Fazel-Najafabadi; Michal Kouril; Behrouz Shamsaei; Juozas Vasiliauskas; Wen Niu; Naim Mahi; Lixia Zhang; Nicholas A Clark; Yan Ren; Shana White; Rashid Karim; Huan Xu; Jacek Biesiada; Mark F Bennett; Sarah E Davidson; John F Reichard; Kurt Roberts; Vasileios Stathias; Amar Koleti; Dusica Vidovic; Daniel J B Clarke; Stephan C Schürer; Avi Ma'ayan; Jarek Meller; Mario Medvedovic
Journal:  Nat Commun       Date:  2022-08-09       Impact factor: 17.694

7.  Differences in peripheral immune system gene expression in frontotemporal degeneration.

Authors:  Russell P Sawyer; Emily J Hill; Jennifer Yokoyama; Mario Medvedovic; Yan Ren; Xiang Zhang; Divaker Choubey; Rhonna S Shatz; Bruce Miller; Daniel Woo
Journal:  Medicine (Baltimore)       Date:  2022-01-21       Impact factor: 1.889

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.